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Endovascular recanalization therapy (ERT) has been a standard of care for patients with acute 
ischemic stroke due to large artery occlusion (LAO) within 6 hours after onset, since five landmark 
ERT trials conducted by 2015 demonstrated its clinical benefit. Recently, two randomized clinical 
trials demonstrated that ERT, even in the late time window of up to 16 hours or 24 hours after 
last known normal time, improved the outcome of patients who had a target mismatch, defined 
as either clinical-core mismatch or perfusion-core mismatch, which prompted the update of na-
tional guidelines in several countries. Accordingly, to provide evidence-based and up-to-date rec-
ommendations for ERT in patients with acute LAO in Korea, the Clinical Practice Guidelines Com-
mittee of the Korean Stroke Society decided to revise the previous Korean Clinical Practice Guide-
lines of Stroke for ERT. For this update, the members of the writing group were appointed by the 
Korean Stroke Society and the Korean Society of Interventional Neuroradiology. After thoroughly 
reviewing the updated evidence from two recent trials and relevant literature, the writing mem-
bers revised recommendations, for which formal consensus was achieved by convening an expert 
panel composed of 45 experts from the participating academic societies. The current guidelines 
are intended to help healthcare providers, patients, and their caregivers make well-informed deci-
sions and to improve the quality of care regarding ERT. The ultimate decision for ERT in a particu-
lar patient must be made in light of circumstances specific to that patient. 
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Introduction 
Previously, five pivotal randomized clinical trials (RCTs) and 
their meta-analysis clearly demonstrated the benefit of endo-
vascular recanalization therapy (ERT), primarily with stent re-
trievers, in patients with acute anterior circulation ischemic 
stroke due to large artery occlusion (LAO).1-6 Of the five RCTs, 
Multicenter Randomized Clinical trial of Endovascular treat-
ment for Acute ischemic stroke in the Netherlands (MR 
CLEAN), Extending the Time for Thrombolysis in Emergency 
Neurological Deficits—Intra-Arterial (EXTEND-IA), and Solitaire 
with the Intention for Thrombectomy as Primary Endovascular 
Treatment (SWIFT PRIME) enrolled patients within 6 hours 
from stroke onset.1-3 Revascularization with Solitaire FR Device 
versus Best Medical Therapy in the Treatment of Acute Stroke 
Due to Anterior Circulation Large Vessel Occlusion Presenting 
within Eight Hours of Symptom Onset (REVASCAT) and Endo-
vascular Treatment for Small Core and Proximal Occlusion 
Ischemic Stroke (ESCAPE) enrolled patients up to 8 or 12 hours 
from stroke onset, but 90.3% of patients in REVASCAT and 
84.5% of those in ESCAPE were enrolled within 6 hours.4,5 
Therefore, major guidelines and statements endorsed ERT up to 
6 hours after symptom onset in patients with LAO in the ante-
rior circulation with the highest level of evidence (LOE) and the 
strongest grade of recommendation (GOR).7-10 According to the 
guidelines, the benefit of ERT was uncertain after 6 hours of 
symptom onset.7,10 Specifically, the previous Korean guidelines 
recommended that “ERT can be considered for patients having 
favorable multimodal imaging profiles regarding expected ben-
efit and safety (LOE IV, GOR C).”10
The proposition “time is brain” also applies to ERT as well as 
to intravenous thrombolysis. The Highly Effective Reperfusion 
evaluated in Multiple Endovascular Stroke Trials (HERMES) col-
laborators showed that the benefit of ERT declined with in-
creasing time from stroke onset to the initiation of ERT, and 
the benefit was not significant after 7.3 hours.11 However, ob-
servational studies have claimed that, even in the late time 
window, many patients still have salvageable tissue readily 
identified with advanced stroke imaging and could benefit 
from reperfusion therapy.12-15 Based on these concepts, diffu-
sion-weighted imaging (DWI) or computerized tomography 
perfusion (CTP) assessment with Clinical Mismatch in the Tri-
age of Wake Up and Late Presenting Strokes Undergoing Neu-
rointervention with Trevo (DAWN) and Endovascular Therapy 
Following Imaging Evaluation for Ischemic Stroke 3 (DEFUSE 3) 
were designed.16,17 These confirmed the benefit of ERT in pa-
tients who had target mismatch, assessed by either clinical-
core mismatch or with perfusion-core mismatch in the ex-
tended time window up to 16 or 24 hours after last known 
normal time (LNT).18,19 The DAWN and DEFUSE 3 results 
prompted the revision of guidelines of United States, Canada, 
and Australia.20-22 The Clinical Practice Guideline (CPG) Com-
mittee of the Korean Stroke Society also decided to update the 
Korean CPG for Stroke, to provide evidence-based and up-to-
date recommendations for ERT in patients with acute LAO. The 
purpose of the current guidelines is to help guide well-in-
formed decisions and to improve the quality of care regarding 
ERT. The ultimate decision for ERT in individual patients must 
be made by the responsible healthcare providers and patients 
and/or their caregivers in light of circumstances specific to the 
individual patient.
Previous guidelines
The previous 2016 Korean CPG for ERT in patients with acute 
ischemic stroke provided the following recommendations, which 
were generated by the available evidence up to May 2015.10 
Endovascular recanalization therapy 
1. In patients with major ischemic stroke due to an acute LAO in 
the anterior circulation (internal carotid artery, M1, and possi-
bly large M2 branch) within 6 hours, ERT is recommended to 
improve clinical outcomes (LOE Ia, GOR A).
2. In patients eligible for intravenous tissue plasminogen activa-
tor (IV-TPA), administration of IV-TPA is recommended before 
the initiation of ERT (LOE Ia, GOR A). Since IV-TPA should not 
significantly delay ERT, it is recommended to simultaneously 
proceed ERT during IV-TPA treatment without waiting for clini-
cal response to IV-TPA.
3. In patients who are contraindicated for IV-TPA, ERT is recom-
mended as a first-line therapy in patients with major ischemic 
stroke due to an acute LAO in the anterior circulation within 6 
hours (LOE IIa, GOR B).
4. In patients with major ischemic stroke due to acute LAO in the 
poster circulation (basilar artery, P1, and vertebral artery) with-
in 6 hours, ERT can be considered (LOE III, GOR B).
5. For patients with acute LAO in the anterior or posterior circula-
tion presenting after 6 hours, ERT can be considered for pa-
tients having favorable multimodal imaging profiles regarding 
expected benefit and safety. Each center is encouraged to de-
fine own selection criteria (LOE IV, GOR C).
6. If indicated, ERT should be initiated as fast as possible (LOE IIa, 
GOR B).
7. Stent-retriever thrombectomy is recommended as a first-line 
ERT (LOE Ia, GOR A).
8. If recanalization is not achieved with stent-retriever thrombec-
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tomy, the addition of other ERT modalities can be considered 
after taking into account the expected efficacy and safety (LOE 
IV, GOR C).
9. Other mechanical thrombectomy or thrombus aspiration devic-
es may be considered as a first-line modality at the discretion 
of responsible interventionists after taking into account techni-
cal aspects (LOE IV, GOR C).
10. During ERT, conscious sedation is generally preferred to general 
anesthesia. However, the decision should be made after consid-
eration of patient’s condition and center’s experience (LOE III, 
GOR B).
Neuroimaging evaluation 
1. Non-contrast computed tomography (CT) or magnetic reso-
nance imaging (MRI) should be conducted to exclude hemor-
rhagic stroke or other non-stroke etiologies (good practice 
points [GPPs]).
2. Non-invasive vascular imaging (CT angiography or magnetic 
resonance [MR] angiography) is recommended to confirm 
acute LAO for patients with major ischemic stroke (GPP).
3. For patients who are not able to perform non-invasive vascular 
imaging, stroke severity or clot sign on non-contrast CT can 
guide decision for ERT (GPP).
4. For selecting patients, neuroimaging evaluation for extensive 
early ischemic injury can guide decision for ERT (GPP).
5. Advanced multimodal imaging to assess collaterals, extent of 
ischemic core, or perfusion-diffusion mismatch can be consid-
ered to identify patients who are likely to benefit from ERT 
(GPP). However, the multimodal imaging should not signifi-
cantly delay ERT.
System organization
1. For centers capable of providing ERT, the organization and im-
plementation of critical pathway and formal protocol are rec-
ommended to accelerate the delivery of ERT (GPP).
2. For centers that are not adequately staffed for ERT, it is en-
couraged to have a referral plan to a center capable of ERT for 
patients eligible for ERT. If indicated, initiating IV-TPA before 
referral is encouraged (GPP).
3. Each center is encouraged to define own criteria for the multi-
disciplinary ERT team that is responsible for initial evaluation, 
decision making, and ERT procedure (GPP).
4. To assess and improve the quality of ERT, each center is en-
couraged to monitor key time metrics of door-to-neuroimaging 
and door-to-groin puncture (GPP).
5. It is encouraged to assess functional outcome, recanalization 
rate, and complication rate after ERT (GPP).
Methodology
Process of the update of the Korean CPG for 
ERT 
In May 2018, the Guideline Oversight Committee of the Korean 
Stroke Society, taking into account the new evidence of ERT 
benefit in the extended time window and its applicability to 
clinical practice in Korea, approved the processes of updating 
the Korean CPG for ERT with regard to purpose and scope, and 
appointed an expert panel for consensus achievement of the 
recommendations prepared by the writing committee members.
The CPG Committee of the Korean Stroke Society assembled 
the writing members appointed by the Korean Stroke Society 
and the Korean Society of Interventional Neuroradiology. In ad-
dition, we organized an expert panel consisting of 45 experts 
(30 from the Korean Stroke Society and 15 from the Korean So-
ciety of Interventional Neuroradiology) to achieve consensus for 
the recommendations proposed by the writing group members. 
In September 2018, the expert panel members reached a 
consensus following a modified Delphi method and the Guide-
line Oversight Committee and the participating academic soci-
eties reviewed and approved the draft prepared by the writing 
members.
 
Evidence search and data analysis
To review the updated information on ERT in the extended 
time window since the publication of the previous CPG in 
2016, we reviewed and assessed RCT results, updated national 
guidelines (published or available online), and relevant articles 
solicited from experts. 
LOE and GORs
We determined the LOE and the GOR for each recommenda-
tion based on the suggestion of the US Agency for Healthcare 
Policy and Research (currently the Agency for Healthcare Re-
search and Quality) (Table 1).23 We used this grading system to 
accord with previous Korean CPGs for stroke. 
Evidence summary 
ERT benefit in the extended time window of 6 
to 24 hours from stroke onset
DAWN
DAWN selected patients with LAO in the anterior circulation 
who could be randomized between 6 and 24 hours from LNT and 
who had a target mismatch between clinical deficit and isch-
emic core.18 From a total of 206 patients enrolled (mean age, 
70.0 years; female, 54.9%), 107 were randomized to the ERT 
10. 
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group (105 patients underwent ERT) and 99 to the control group. 
The majority of the patients (78%) had an occlusion in the first 
segment of the middle cerebral artery (MCA), followed by the in-
tracranial internal carotid artery (19.9%) and the second seg-
ment of MCA (2.4%). The median interval from LNT to random-
ization was 12.2 hours versus 13.3 hours, the baseline median 
National Institute of Health Stroke Scale (NIHSS) score was 17 
versus 17, and the median infarct volume at baseline was 7.6 
and 8.9 mL in the ERT group and the control group, respectively. 
The primary endpoint, the mean score for disability on the 
90-day utility-weighted modified Rankin Scale (mRS) (range, 0 
[death] to 10 [no symptoms or disability]), was significantly 
higher in the ERT group than in the control group (5.5 points vs. 
3.4 points; adjusted difference, 2.0 points; 95% confidence in-
terval [CI], 1.1 to 3.0; posterior probability of superiority, 
>0.999). In a conventional dichotomized mRS analysis, the pro-
portion of 90-day mRS 0–2 was also significantly higher in the 
ERT group than in the control group (49% vs. 13%; adjusted 
difference, 33%; 95% credible interval, 21 to 44; posterior 
probability of superiority, >0.999). There was no heterogeneity 
of the treatment effect on the utility-weighted mRS score in 
any of the pre-specified subgroups. The findings indicate that, 
for every two patients treated with ERT, one additional patient 
had a clinically meaningful improvement in the 90-day disabili-
ty degree, and for every 2.8 patients treated with ERT, one addi-
tional patient had a 90-day functional independence (mRS 
0–2). There were no differences in the rate of symptomatic in-
tracranial hemorrhage (6% vs. 3%, P=0.50) and 90-day mortal-
ity (19% vs. 18%, P=1.00) between the ERT and control groups.
The clinical benefit observed in DAWN was driven by suc-
cessful reperfusion with ERT. In the ERT arm, 84% of patients 
achieved successful recanalization defined as grade 2b or 3 on 
the modified Thrombolysis in Cerebral Infarction (mTICI) scale 
at a median interval of 13.6 hours from LNT to reperfusion. The 
ERT group compared to the control group had significantly 
higher rates of early response (decrease in the NIHSS score ≥10 
points or an NIHSS score 0–1 within 7 days or at discharge) 
and recanalization at 24 hours, and had significantly lower in-
farct volume and infarct growth at 24 hours. 
DEFUSE 3
DEFUSE 3 selected patients with LAO in the anterior circulation 
who could be started on ERT in 6 to 16 hours from LNT and 
who had a target mismatch assessed by ischemic core and 
penumbral regions from CTP or diffusion and perfusion MRI 
images.19 Of the 182 patients enrolled (median age, 70 years; 
female, 50.5%), 92 were randomized to the ERT group (90 pa-
tients underwent ERT) and 90 to the control group. In 114 pa-
tients, the occlusion site was the MCA (63%; 113 in the M1 
segment and one in the M2 segment) and in 68 (37%), the in-
tracranial ICA. In the ERT group versus the control group, the 
median interval from LNT to randomization was 10.9 hours 
versus 10.7 hours; the baseline median NIHSS score, 16 versus 
16; the median ischemic core volume at baseline, 9.4 mL ver-
sus 10.1 mL; and the median perfusion deficit volume, 114.7 
mL versus 116.1 mL; respectively. 
The primary endpoint, the 90-day mRS score distribution, was 
more favorable in the ERT group than in the control group (un-
adjusted common odds ratio, 2.77; 95% CI, 1.63 to 4.70; 
P<0.001). The proportion of patients who achieved 90-day mRS 
Table 1. Level of evidence and grade of recommendation
LOE
Ia Evidence obtained from meta-analysis of randomized controlled trials
Ib Evidence obtained from at least one randomized controlled trial
IIa Evidence obtained from at least one well-designed controlled study without randomization
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study
III Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case 
studies
IV Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities
GOR
A (LOE Ia, Ib) Required: at least one randomized controlled trial as part of the body of literature of overall good quality and consistency addressing 
specific recommendation
B (LOE IIa, IIb, III) Required: availability of well conducted clinical studies but no randomized clinical trials on the topic of recommendation
C (LOE IV) Required: evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. This grade 
indicates absence of directly applicable clinical studies of good quality
GPP Recommended best practice based on the clinical experience of the guideline development group
LOE, level of evidence; GOR, grade of recommendation; GPP, good practice point.
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0–2 was substantially higher in the ERT group than in the con-
trol group (45% vs. 17%; unadjusted risk ratio, 2.67; 95% CI, 
1.60 to 4.48; P<0.001). The treatment effect on the 90-day mRS 
distribution was consistent across the pre-specified subgroups.
In the ERT group, 76% achieved mTICI 2b or 3 reperfusion at 
median interval of 11.5 hours from LNT. At 24 hours, infarct 
volume (35 mL vs. 41 mL) and infarct growth (23 mL vs. 33 mL) 
were lower in the ERT group than in the control group, but the 
difference was not statistically significant. However, the rates 
of 24-hour complete recanalization and reperfusion >90% 
were increased (over 4-fold) with ERT.
There was no difference in the rate of symptomatic intracra-
nial hemorrhage between the ERT group and the control group 
(7% vs. 4%, P=0.75), but the 90-day mortality rate was mar-
ginally lower in the ERT group than in the control group (14% 
vs. 26%, P=0.05). 
Patient selection for ERT in the extended time 
window 
Time window
The time window differed between DAWN and DEFUSE 3; the 
eligible time window from LNT was 6 to 24 hours in DAWN 
and 6 to 16 hours in DEFUSE 3. However, the median interval 
between LNT and randomization was 12.8 hours in DAWN and 
10.8 hours in DEFUSE 3, and the median interval between LNT 
and reperfusion in the ERT group was 13.6 hours in DAWN and 
12.1 hours in DEFUSE 3. Therefore, patients enrolled in the two 
trials had a similar time window of about 12 hours from LNT 
and a comparable interval from LNT to reperfusion of about 13 
hours for patients receiving ERT. 
In subgroup analyses, the ERT benefit remained significant in 
patients randomized after 12 hours in both trials. In DEFUSE 3, 
there was a trend of greater ERT benefit in patients randomized 
after 12 hours, although the interaction of the treatment effect 
to the time of randomization was not significant. Taken together, 
the common time window of the two trials was up to 16 hours, 
but ERT may benefit up to 24 hours in highly selected patients.
Identification of patients with target mismatch in DAWN 
and DEFUSE 3
DAWN used clinical-core mismatch that was adjusted by age 
and stroke severity.16,18 For patients who were ≥80 years and 
had the NIHSS score ≥10, the ischemic core volume should be 
less than 21 mL. For patients aged <80 years, the ischemic core 
volume should be less than 31 mL in those with the NIHSS 
score 10 to 19, and it should be 31 mL to less than 51 mL in 
those with the NIHSS score ≥20. The ischemic core volume was 
assessed by DWI or CTP using the automated software (RAPID, 
iSchemaView, Menlo Park, CA, USA).
DEFUSE 3 used perfusion-core mismatch and the eligible mis-
match criteria from CTP or DWI/perfusion-weighted imaging 
(PWI) MRI scans were (1) an ischemic core volume <70 mL; (2) a 
ratio of ischemic tissue volume (perfusion deficit area defined 
with time to maximum of residue function [Tmax] exceeding 6 
seconds on perfusion imaging) to initial ischemic core volume 
≥1.8; and (3) an absolute penumbra volume ≥15 mL.19 DEFUSE 3 
used the automated software (RAPID) to assess the imaging pro-
files. Moreover, DEFUSE 3 allowed enrollments of patients with 
LAO in the anterior circulation and small ischemic core (DWI 
volume <25 mL) if PWI MRI or CTP was technically inadequate.
The two trials differed in the evaluation of target mismatch: 
clinical-core versus perfusion-core mismatch. In addition, to 
assess ischemic core volume, the two trials used the same au-
tomated program (RAPID), although the thresholds of ischemic 
core volume for eligibility were different. However, patients 
enrolled in DAWN and DEFUSE 3 were generally comparable; 
for patients treated with ERT, the median ischemic core volume 
was 7.6 mL (interquartile range [IQR], 2.0 to 18.0) in DAWN 
and 9.4 mL (IQR, 2.3 to 25.6) in DEFUSE 3, and the median NI-
HSS score was 17 mL (IQR, 13 to 21) in DAWN and 16 mL (IQR, 
10 to 20) in DEFUSE 3. The control groups in the two trials also 
had comparable characteristics. Therefore, small ischemic core 
and severe deficit—whether it was defined by clinical measure 
or perfusion imaging—attributed to ICA or M1 segment, were 
the key features of the enrolled patients.
Identifying patients with target mismatch in real world 
clinical practice
The assessment of ischemic core or target mismatch in patients 
presenting beyond 6 hours with the automated software that 
was used and qualified by the DAWN and DEFUSE 3 trials was 
preferred. The 2018 United States guidelines recommend adher-
ing to the DAWN or DEFUSE 3 eligibility criteria.20 The 2018 up-
dated Canadian stroke guidelines also recommend following the 
DAWN and DEFUSE 3 criteria. Given that a CT-based approach 
rather than an MRI-based approach is more available in most 
Canadian centers, the Canadian guidelines recommend CTP im-
aging and the use of software that can provide reproducible ob-
jective measurements of ischemic core and penumbra.21 In con-
trast, the Australian guidelines provide a more flexible recom-
mendation to undertake ERT between 6 to 24 hours from LNT if 
clinical and CTP or MRI features indicate the presence of sal-
vageable brain tissue.22 In Korea, most stroke centers are not 
equipped with the RAPID software, and accordingly they need to 
define their own imaging and/or clinical criteria that can be 
readily available on-site and reasonably select eligible patients. 
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It may be an issue how reliably stroke experts can identify 
patients eligible for ERT based on clinical features and multi-
modal imaging readily available on-site, without relying on a 
validated software program. Previously, the DEFUSE 3 investi-
gators conducted a multicenter cohort study, which aimed to 
evaluate the validity of CTP assessed by the RAPID software for 
identifying target mismatch in patients treated with ERT as a 
foundation study for DEFUSE 3. For the decision making for 
ERT, the participating investigators used non-contrast CT, CT 
angiogram (CTA), and CTP of their own routine protocols, and 
were instructed not to use the RAPID software.13 Among the 
total of 190 patients treated with ERT based on their clinical 
and imaging features, 131 patients (69%) were later identified 
to have target mismatch on the RAPID software assessment. Of 
note, the proportion of patients having target mismatch was 
62% in the <6-hour window, but increased to 80% in the >6-
hour window (83% in the 6- to 9-hour window, 85% in the 9- 
to 12-hour window, and 69% in the >12-hour window). 
Among 170 patients who achieved successful reperfusion, the 
proportion of 90-day mRS 0–2 was 59% (n=100), which was 
less than 66% among patients (n=114) who had mismatch 
profile and achieved reperfusion, but seemed acceptably high. 
Furthermore, among all 190 patients, the proportion of 90-day 
mRS 0–2 was about 55%, which is likely higher than the 46% 
observed in the ERT arm of the HERMES collaborative study. 
The rate of symptomatic intracerebral hemorrhage was 5.2% 
of all patients and was not influenced by the target mismatch 
status. Taken together, even without automated software pro-
cessing, stroke experts appeared to identify reasonably patients 
who had target mismatch with clinical features and routinely 
available multimodal imaging, even more selectively identify-
ing patients presenting in the later time window. 
Academic and commercial automated programs have been 
developed and are under development. It is generally accepted 
that, for the assessment of ischemic core and/or target mis-
match, automated quantitative imaging analyses outperform 
qualitative measures, and some centers in Korea might cur-
rently use one of these programs in clinical practice. However, 
comparative studies showed that there were discrepancies in 
perfusion maps generated among commercial programs, and 
academic programs compared to commercial programs were 
generally more accurate in the analysis of perfusion maps.24-26 
Therefore, clinicians should recognize the limitations of each 
software program available in their centers. 
Several studies have clearly demonstrated that patients with 
good collateral circulation had a greater benefit from ERT. 
DAWN and DEFUSE 3 did not consider the status of collateral 
circulation for eligibility and the effect of collateral circulation 
status on the ERT benefit has not been well studied in the late 
time window. In general, patients with clear onset and a small 
ischemic core, even in the late time window, are likely to have 
good collateral circulation. However, in patients with unknown 
onset time, the small ischemic core does not always indicate 
good collateral circulation, which could determine the speed of 
infarct progression and the response to ERT. The international 
stroke expert groups strongly recommend to assess collateral 
circulation assessment as well as LAO, ischemic core, and tar-
get mismatch for potential ERT candidates.27 The Canadian 
guidelines also suggest that moderate-to-good collateral sta-
tus on CTA predict a better response to ERT.21 Because of lack 
of clear evidence in the extended time window, no specific rec-
ommendation for the collateral assessment is provided in the 
current updated guidelines, but it should be considered for pa-
tient selection, especially for those with unclear onset time.
Consensus achievement
The writing members prepared the updated recommendations 
based on available evidence and their practical applicability to 
the healthcare system in Korea. To achieve consensus for the 
proposed recommendations using a modified Delphi method, 
we convened a panel of 45 experts of neurologists, interven-
tional radiologists, and neurosurgeons: 30 from the Korean 
Stroke Society and 15 from the Korean Society of Intervention-
al Neuroradiology. Using a 9-point scale (a score of 9 as strong 
agreement and a score of 1 as strong disagreement) modified 
from the RAND Corporation method,28 the expert panel mem-
bers were asked to individually provide their ratings on each 
recommendation. We defined scores 7–9 as agreement, 4–6 as 
uncertainty, and 1–3 as disagreement. For each recommenda-
tion, if ≥75% of the participating panel members agreed (pro-
viding a 7–9 score), it was regarded as a consensus for that 
recommendation. If the agreement rate was <75%, additional 
Delphi rounds were planned with revised recommendations. 
The current updated guidelines are intended to focus on the 
ERT in the extended time window. Therefore, the panel mem-
bers were first asked whether it is necessary to update the rec-
ommendation of ERT between 6 to 24 hours from LNT. They 
were also asked whether multimodal imaging available on-site 
other than the RAPID software program could be used to select 
patients eligible for ERT between 6 to 24 hours. Then, they 
were asked to choose one of the following recommendations, 
taking into account evidence and applicability in Korea. (1) “In 
selected patients with acute ischemic stroke due to LAO in the 
anterior circulation presenting within 6 to 24 hours from last 
seen normal, ERT is recommended when the patients meet the 
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Table 2. Summary of current recommendations
Comment
ERT
1. In patients with major ischemic stroke due to an acute large artery occlusion in the anterior circulation (internal carotid ar-
tery, M1, and possibly large M2 branch) within 6 hours, ERT is recommended to improve clinical outcomes (LOE Ia, GOR A).
No change
2. In patients eligible for IV-TPA, administration of IV-TPA is recommended before the initiation of ERT (LOE Ia, GOR A). Since 
IV-TPA should not significantly delay ERT, it is recommended to simultaneously proceed ERT during IV-TPA treatment 
without waiting for clinical response to IV-TPA.
No change
3. In patients who are contraindicated for IV-TPA, ERT is recommended as a first-line therapy in patients with major ischemic 
stroke due to an acute large artery occlusion in the anterior circulation within 6 hours (LOE IIa, GOR B).
No change
4. In patients with major ischemic stroke due to acute large artery occlusion in the poster circulation (basilar artery, P1, and 
vertebral artery) within 6 hours, ERT can be considered (LOE III, GOR B).
No change
5. In selected patients with acute ischemic stroke due to large vessel occlusion in the anterior circulation presenting within 6 
to 24 hours from last seen normal, ERT can be recommended when the patients have target mismatch assessed by multi-
modal imaging and/or clinical deficit & when reperfusion by ERT is expected to improve the outcome of patients. For pa-
tient selection, each institution is recommended to have its own criteria, which can help in the timely and reasonable 
identification of patients with target mismatch in the late time window (LOE III, GOR C). 
New recommendation
6. In selected patients with acute ischemic stroke due to large vessel occlusion in the posterior circulation presenting after 6 
hours, ERT can be considered for patients having favorable multimodal imaging profiles in consideration of risks and ben-
efits. Each center is encouraged to define its own patient selection criteria (LOE IV, GOR C). 
No change
If indicated, ERT should be initiated as fast as possible (LOE IIa, GOR B). No change
7. Stent-retriever thrombectomy is recommended as a first-line ERT (LOE Ia, GOR A). No change
8. If recanalization is not achieved with stent-retriever thrombectomy, the addition of other ERT modalities can be consid-
ered after taking into account the expected efficacy and safety (LOE IV, GOR C).
No change
9. Other mechanical thrombectomy or thrombus aspiration devices may be considered as a first-line modality at the discre-
tion of responsible interventionists after taking into account technical aspects (LOE IV, GOR C).
No change
10. During ERT, conscious sedation is generally preferred to general anesthesia. However, the decision should be made after 
consideration of patient’s condition and center’s experience (LOE III, GOR B).
No change
Neuroimaging evaluation
1. Non-contrast CT or MRI should be conducted to exclude hemorrhagic stroke or other non-stroke etiologies (LOE III, GOR C). Revised from previous LOE
2. Non-invasive vascular imaging (CT angiography or MR angiography) is recommended to confirm acute large artery occlu-
sion for patients with major ischemic stroke (LOE III, GOR C).
Revised from previous LOE
3. For patients who are not able to perform non-invasive vascular imaging, stroke severity or clot sign on non-contrast CT 
can guide decision for ERT (GPP).
No change
4. For selecting patients, neuroimaging evaluation for extensive early ischemic injury can guide decision for ERT (GPP). No change
5. In selected patients who present within 6 to 24 hours from last seen normal, multimodal imaging for assessing collaterals, 
infarct core, or perfusion (or clinical)-diffusion mismatch is recommended to select eligible patients for ERT. Each center is 
encouraged to define its own imaging modality to timely identify target mismatch (LOE III, GOR C). 
New recommendation
System organization 
1. For centers capable of providing ERT, the organization and implementation of a critical pathway and a formal protocol are 
recommended to accelerate the delivery of ERT (GPP).
No change
2. For centers that are not adequately staffed for ERT, it is encouraged to have a referral plan to a center capable of ERT for 
patients eligible for ERT. If indicated, initiating IV-TPA before referral is encouraged (GPP).
No change
3. Each center is encouraged to define own criteria for the multidisciplinary ERT team that is responsible for initial evalua-
tion, decision-making, and ERT procedure (GPP).
No change
4. To assess and improve the quality of ERT, each center is encouraged to monitor key time metrics of door-to-neuroimaging 
and door-to-groin puncture (GPP).
No change
5. It is encouraged to assess functional outcome, recanalization rate, and complication rate after ERT (GPP). No change
ERT, endovascular recanalization therapy; LOE, level of evidence; GOR, grade of recommendation; IV-TPA, intravenous tissue plasminogen activator; CT, com-
puted tomography; MRI, magnetic resonance imaging; MR, magnetic resonance; GPP, good practice point. 
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DAWN or DEFUSE 3 eligibility criteria (LOE Ib, GOR A)” or (2) “In 
selected patients with acute ischemic stroke due to LAO in the 
anterior circulation presenting within 6 to 24 hours from last 
seen normal, ERT can be recommended when the patients have 
target mismatch assessed by multimodal imaging and/or clini-
cal deficit & when reperfusion by ERT is expected to improve 
the outcome of the patients. For patient selection, each insti-
tution is recommended to have its own criteria, which can 
timely and reasonably identify patients with target mismatch 
in the late time window (LOE III, GOR C).” For the second pro-
posal, we graded the LOE as III and the GOR as C because the 
validity of multimodal imaging available on-site has not been 
confirmed by clinical trials. 
Urgent neuroimaging studies are necessary to exclude hem-
orrhagic stroke or stroke mimics. In a cost-effective analysis, 
immediate CT scanning improved clinical outcome partly at-
tributed to timely management decision and appropriate treat-
ment, which translated to better quality of life.29 In addition, 
MRI versus CT was comparable to detect hemorrhagic stroke or 
acute vascular lesion.30,31 In addition, for potential ERT candi-
dates, an LAO should be confirmed by non-invasive vascular 
imaging (CTA or MR angiography). Since these pieces of evi-
dence were not reflected in the previous recommendation, the 
panel members were asked whether they agreed to upgrade 
the LOE and GOR from ‘GPP’ to ‘LOE III and GOR C’ for the rec-
ommendations of non-contrast CT or MRI to exclude hemor-
rhagic stroke or other non-stroke etiologies and non-invasive 
vascular imaging for patients with major ischemic stroke. 
Among the 45 experts invited, 41 (91%) provided their rat-
ings (list of responding participants in Supplementary Table 1). 
In the first Delphi round, consensus was achieved in all ques-
tion items and recommendations, and the scores and agree-
ment rates were generally high (Supplementary Table 2). In 
particular, for the selection of patients eligible for ERT in the 
extended time window, the expert panel members agreed to 
recommend multimodal imaging available on-site rather than 
the specific RAPID software program. The final draft of the cur-
rent guidelines was reviewed and approved by the participating 
academic societies.
Recommendations
Updated Recommendations for ERT, neuroimaging evaluation, 
and system organization are summarized in Table 2 and Sup-
plementary Table 3.
Impact of expanding the time window 
of ERT on clinical practice in Korea
Expanding the time window of ERT up to 24 hours will have a 
significant impact on the stroke care system in Korea. In a single 
comprehensive center study in United States, only 1.7% of all 
patients with acute ischemic stroke admitted met the DAWN 
trial eligibility and 2.7% met the DAWN or DEFSUE-3 criteria.32 
In a Korean study analyzing 6,742 patients enrolled in a multi-
center registry between May 2011 and December 2012, 1.1% 
met the DAWN criteria. Based on these observations, the age- 
and sex-specific ischemic stroke incidence data,33 and the 2016 
Korean population data, the estimated nationwide annual num-
ber of patients who could meet the DAWN criteria was 1,331 in 
Korea.34 Therefore, despite the small number of patients eligible 
for the extended ERT time window in individual centers, the na-
tionwide number of patients would not be negligible. According 
to the 2017 nationwide insurance claim database, approxi-
mately 3,500 patients were treated with ERT in Korea (personal 
communication with Byung Moon Kim in 2018). Therefore, ERT 
candidates could be increased by 38% by expanding the time 
window for ERT. However, to identify these patients, an addi-
tional 23.7% of all patients with acute ischemic stroke should 
be urgently screened.34 Furthermore, given that patients with 
suspected stroke should also be screened in the extended time 
window, responsible stroke experts will have a substantially in-
creased burden, and should be supported accordingly with cor-
responding resource allocation.
Supplementary materials
Supplementary materials related to this article can be found 
online at https://doi.org/10.5853/jos.2019.00024.
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Supplementary Table 2. Results of Delphi consensus









Is it necessary to update the recommendations of ERT between 6–24 hours 
from last known normal time considering current clinical practice in Korea?
First round 97.6 0.0 2.4
Could multimodal imaging available on-site, other than the RAPID software 
program, be used to select patients eligible for ERT between 6–24 hours?
First round 82.9 9.8 7.3
ERT
Recommendation 5: Option #1
5. In selected patients with acute ischemic stroke due to large vessel occlusion 
in the anterior circulation presenting within 6 to 24 hours from last seen 
normal, ERT is recommended when the patients meet the DAWN or DEFUSE 
3 eligibility criteria (LOE Ib, GOR A)
First round 29.3 31.7 36.6
Recommendation 5: Option #2
5. In selected patients with acute ischemic stroke due to large vessel occlusion 
in the anterior circulation presenting within 6 to 24 hours from last seen 
normal, ERT can be recommended when the patients have target mismatch 
assessed by multimodal imaging and/or clinical deficit & when reperfusion 
by ERT is expected to improve the outcome of patients. For patient selection, 
each institution is recommended to have its own criteria, which aids in the 
timely and reasonable identification of patients with target mismatch in the 
late time window (LOE III, GOR C).
First round 80.5 17.1 2.4
6. In selected patients with acute ischemic stroke due to large vessel occlusion 
in the posterior circulation presenting after 6 hours, ERT can be considered 
for patients having favorable multimodal imaging profiles in consideration 
of risks and benefits. Each center is encouraged to define its own patient se-
lection criteria (LOE IV, GOR C).
First round 92.7 7.3 0.0
Neuroimaging evaluation
1. Non-contrast CT or MRI should be conducted to exclude hemorrhagic 
stroke or other non-stroke etiologies (LOE III, GOR C).
First round 95.1 4.9 0.0
2. Non-invasive vascular imaging (CT angiography or MR angiography) is rec-
ommended to confirm acute large artery occlusion for patients with major 
ischemic stroke (LOE III, GOR C).
First round 95.1 4.9 0.0
5. In selected patients who present within 6 to 24 hours from last seen nor-
mal, multimodal imaging for assessing collaterals, infarct core, or perfusion 
(or clinical)-diffusion mismatch is recommended to select eligible patients 
for ERT. Each center is encouraged to define its own imaging modality to 
timely identify target mismatch (LOE III, GOR C).
First round 85.4 4.9 7.3
ERT, endovascular recanalization therapy; DAWN, Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention with 
Trevo; DEFUSE 3, Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3; LOE, level of evidence; GOR, grade of recommendation; CT, com-
puted tomography; MRI, magnetic resonance imaging; MR, magnetic resonance.
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Supplemental Table 3. Comparison of changes in recommendations between previous and revised guidelines
Previous guideline in 2016 Updated guideline in 2019
ERT 5. For patients with acute large artery occlusion in the anterior or 
posterior circulation presenting after 6 hours, ERT can be consid-
ered for patients having favorable multimodal imaging profiles 
regarding expected benefit and safety. Each center is encouraged 
to define its own selection criteria (LOE IV, GOR C).
5. In selected patients with acute ischemic stroke due to large ves-
sel occlusion in the anterior circulation presenting within 6 to 24 
hours from last seen normal, ERT can be recommended when pa-
tients have target mismatch assessed by multimodal imaging and/
or clinical deficit & when reperfusion by ERT is expected to im-
prove the outcome of patients. For patient selection, each institu-
tion is recommended to have its own criteria, which can help in 
the timely and reasonable identification of patients with target 
mismatch in the late time window (LOE III, GOR C).
Neuroimaging 
evaluation
1. Non-contrast CT or MRI should be conducted to exclude hemor-
rhagic stroke or other non-stroke etiologies (GPP).
1. Non-contrast CT or MRI should be conducted to exclude hemor-
rhagic stroke or other non-stroke etiologies (LOE III, GOR C).
2. Non-invasive vascular imaging (CT angiography or MR angiogra-
phy) is recommended to confirm acute large artery occlusion for 
patients with major ischemic stroke (GPP).
2. Non-invasive vascular imaging (CT angiography or MR angiogra-
phy) is recommended to confirm acute large artery occlusion for 
patients with major ischemic stroke (LOE III, GOR C)
5. In selected patients who present within 6 to 24 hours from last 
seen normal, multimodal imaging for assessing collaterals, infarct 
core, or perfusion (or clinical)-diffusion mismatch is recommend-
ed to select eligible patients for ERT. Each center is encouraged to 
define its own imaging modality to timely identify target mis-
match (LOE III, GOR C).
ERT, endovascular recanalization therapy; LOE, level of evidence; GOR, grade of recommendation; CT, computed tomography; MRI, magnetic resonance imag-
ing; GPP, good practice point; MR, magnetic resonance.
